Skip to content

Study · Systematic review · 2025

13 results

IDeglira vs insulin degludec for type 2 diabetes: a systematic review and meta-analysis.

Liu Y, Li X, Yang J, Qie S, Wang X, Wang X, Zheng Y

Frontiers in endocrinology1 Sept 2025Cited by 1 (Europe PMC)

PMID40958912 (opens in a new tab)PMCIDPMC12434752 (opens in a new tab)DOI10.3389/fendo.2025.1643386 (opens in a new tab)PepBankPUB-40958912
Download PDFPubMedAsk about this study
Jump to 13 results

Summary

ObjectivesThis systematic review and meta-analysis was to evaluate and compare the efficacy and safety profiles of IDegLira versus insulin degludec in the management of type 2 diabetes (T2D).MethodsA comprehensive search was systematically conducted across PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov from their inception until March 11, 2025. The search focused on randomized controlled trials (RCTs) that compared IDegLira with insulin degludec in adult patients with T2D. The primary outcomes of interest included change in glycated hemoglobin (HbA1c) and body weight. Random-effects meta-analyses were performed using RevMan 5.4 and Stata 16.0 software.ResultsA total of six eligible RCTs, encompassing 3,393 patients (2,075 receiving IDegLira and 1,318 receiving insulin degludec), were included in the analysis. Treatment with IDegLira resulted in significant reductions in HbA1c (MD -0.79%, 95%CI: -1.03% to -0.54%), body weight (MD -1.62 kg, 95% CI: -2.13 kg to -1.11 kg), fasting plasma glucose (MD -0.45 mmol/L, 95% CI: -0.77 mmol/L to -0.14 mmol/L), self-measured plasma glucose (MD -1.00 mmol/L, 95% CI: -1.42 mmol/L to -0.59 mmol/L), and systolic blood pressure (MD -2.23 mmHg, 95% CI: -3.63 mmHg to -0.82 mmHg). In comparison to insulin degludec, IDegLira demonstrated superior blood glucose control, as evidenced by a higher proportion of patients achieving HbA1c levels below 7.0% and 6.5%, as well as those achieving these targets without weight gain and severe or blood glucose-confirmed hypoglycemic episodes. Additionally, patients treated with IDegLira required significantly lower daily insulin doses. Notably, the risk of severe or blood glucose-confirmed symptomatic hypoglycemia, adverse events, and severe adverse events was comparable between IDegLira and insulin degludec.ConclusionsThis meta-analysis provides compelling evidence that IDegLira offers superior glycemic control and more favorable effects on body weight compared to insulin degludec, while maintaining a comparable safety profile.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In T2D adults, adding liraglutide to insulin degludec reduced HbA1c versus degludec alone (MD -0.79 %, 95% CI -1.03 to -0.54).

    In plain wordsIn T2D adults, IDegLira lowered HbA1c more than insulin degludec.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference
    −0.79%
    IDegLira versus insulin degludec
    95% CI
    −1.03 to −0.54%
    native added-peptide contrast

    Source sentences

    Summary
    HbA1c (MD -0.79%, 95%CI: -1.03% to -0.54%)
    5 context sentences
    Summary · context
    Treatment with IDegLira resulted in significant reductions
    Summary · context
    A comprehensive search was systematically conducted across PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov from their inception until March 11, 2025.
    Summary · context
    The search focused on randomized controlled trials (RCTs) that compared IDegLira with insulin degludec in adult patients with T2D.
    Summary · context
    The primary outcomes of interest included change in glycated hemoglobin (HbA1c) and body weight.
    Summary · context
    Random-effects meta-analyses were performed using RevMan 5.4 and Stata 16.0 software.
  2. 02HumanSystematic reviewEfficacy outcome

    In T2D adults, adding liraglutide to insulin degludec reduced body weight versus degludec alone (MD -1.62 kg, 95% CI -2.13 to -1.11).

    In plain wordsIn T2D adults, IDegLira lowered body weight more than insulin degludec.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference
    −1.62 kg
    IDegLira versus insulin degludec
    95% CI
    −2.13 to −1.11 kg
    native added-peptide contrast

    Source sentences

    Summary
    body weight (MD -1.62 kg, 95% CI: -2.13 kg to -1.11 kg)
    5 context sentences
    Summary · context
    Treatment with IDegLira resulted in significant reductions
    Summary · context
    A comprehensive search was systematically conducted across PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov from their inception until March 11, 2025.
    Summary · context
    The search focused on randomized controlled trials (RCTs) that compared IDegLira with insulin degludec in adult patients with T2D.
    Summary · context
    The primary outcomes of interest included change in glycated hemoglobin (HbA1c) and body weight.
    Summary · context
    Random-effects meta-analyses were performed using RevMan 5.4 and Stata 16.0 software.
  3. 03HumanSystematic reviewEfficacy outcome

    In T2D adults, adding liraglutide to insulin degludec reduced fasting glucose versus degludec alone (MD -0.45 mmol/L, 95% CI -0.77 to -0.14).

    In plain wordsIn T2D adults, IDegLira lowered fasting glucose more than insulin degludec.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting plasma glucose
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference
    −0.45 mmol/L
    IDegLira versus insulin degludec
    95% CI
    −0.77 to −0.14 mmol/L
    native added-peptide contrast

    Source sentences

    Summary
    fasting plasma glucose (MD -0.45 mmol/L, 95% CI: -0.77 mmol/L to -0.14 mmol/L)
    5 context sentences
    Summary · context
    Treatment with IDegLira resulted in significant reductions
    Summary · context
    A comprehensive search was systematically conducted across PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov from their inception until March 11, 2025.
    Summary · context
    The search focused on randomized controlled trials (RCTs) that compared IDegLira with insulin degludec in adult patients with T2D.
    Summary · context
    The primary outcomes of interest included change in glycated hemoglobin (HbA1c) and body weight.
    Summary · context
    Random-effects meta-analyses were performed using RevMan 5.4 and Stata 16.0 software.
  4. 04HumanSystematic reviewEfficacy outcome

    In T2D adults, adding liraglutide to insulin degludec reduced self-measured glucose versus degludec alone (MD -1.0 mmol/L, 95% CI -1.42 to -0.59).

    In plain wordsIn T2D adults, IDegLira lowered self-measured glucose more than insulin degludec.

    Peptide
    Liraglutide
    Outcome
    DecreaseSelf-measured plasma glucose
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference
    −1 mmol/L
    IDegLira versus insulin degludec
    95% CI
    −1.42 to −0.59 mmol/L
    native added-peptide contrast

    Source sentences

    Summary
    self-measured plasma glucose (MD -1.00 mmol/L, 95% CI: -1.42 mmol/L to -0.59 mmol/L)
    5 context sentences
    Summary · context
    Treatment with IDegLira resulted in significant reductions
    Summary · context
    A comprehensive search was systematically conducted across PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov from their inception until March 11, 2025.
    Summary · context
    The search focused on randomized controlled trials (RCTs) that compared IDegLira with insulin degludec in adult patients with T2D.
    Summary · context
    The primary outcomes of interest included change in glycated hemoglobin (HbA1c) and body weight.
    Summary · context
    Random-effects meta-analyses were performed using RevMan 5.4 and Stata 16.0 software.
  5. 05HumanSystematic reviewEfficacy outcome

    In T2D adults, adding liraglutide to insulin degludec reduced systolic blood pressure versus degludec alone (MD -2.23 mmHg, 95% CI -3.63 to -0.82).

    In plain wordsIn T2D adults, IDegLira lowered systolic blood pressure more than insulin degludec.

    Peptide
    Liraglutide
    Outcome
    DecreaseSystolic blood pressure
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Mean difference
    −2.23 mmHg
    IDegLira versus insulin degludec
    95% CI
    −3.63 to −0.82 mmHg
    native added-peptide contrast

    Source sentences

    Summary
    systolic blood pressure (MD -2.23 mmHg, 95% CI: -3.63 mmHg to -0.82 mmHg)
    5 context sentences
    Summary · context
    Treatment with IDegLira resulted in significant reductions
    Summary · context
    A comprehensive search was systematically conducted across PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov from their inception until March 11, 2025.
    Summary · context
    The search focused on randomized controlled trials (RCTs) that compared IDegLira with insulin degludec in adult patients with T2D.
    Summary · context
    The primary outcomes of interest included change in glycated hemoglobin (HbA1c) and body weight.
    Summary · context
    Random-effects meta-analyses were performed using RevMan 5.4 and Stata 16.0 software.
  6. 06HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, IDegLira produced a higher proportion achieving HbA1c below 7.0% than insulin degludec.

    In plain wordsIn adults with type 2 diabetes, more people on IDegLira reached HbA1c below 7.0% than on insulin degludec.

    Peptide
    Liraglutide
    Outcome
    IncreaseHbA1c below 7.0%
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In comparison to insulin degludec, IDegLira demonstrated superior blood glucose control, as evidenced by a higher proportion of patients achieving HbA1c levels below 7.0% and 6.5%, as well as those achieving these targets without weight gain and severe or blood glucose-confirmed hypoglycemic episodes.
    4 context sentences
    Summary · context
    A comprehensive search was systematically conducted across PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov from their inception until March 11, 2025.
    Summary · context
    The search focused on randomized controlled trials (RCTs) that compared IDegLira with insulin degludec in adult patients with T2D.
    Summary · context
    The primary outcomes of interest included change in glycated hemoglobin (HbA1c) and body weight.
    Summary · context
    Random-effects meta-analyses were performed using RevMan 5.4 and Stata 16.0 software.
  7. 07HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, IDegLira produced a higher proportion achieving HbA1c below 6.5% than insulin degludec.

    In plain wordsIn adults with type 2 diabetes, more people on IDegLira reached HbA1c below 6.5% than on insulin degludec.

    Peptide
    Liraglutide
    Outcome
    IncreaseHbA1c below 6.5%
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In comparison to insulin degludec, IDegLira demonstrated superior blood glucose control, as evidenced by a higher proportion of patients achieving HbA1c levels below 7.0% and 6.5%, as well as those achieving these targets without weight gain and severe or blood glucose-confirmed hypoglycemic episodes.
    4 context sentences
    Summary · context
    A comprehensive search was systematically conducted across PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov from their inception until March 11, 2025.
    Summary · context
    The search focused on randomized controlled trials (RCTs) that compared IDegLira with insulin degludec in adult patients with T2D.
    Summary · context
    The primary outcomes of interest included change in glycated hemoglobin (HbA1c) and body weight.
    Summary · context
    Random-effects meta-analyses were performed using RevMan 5.4 and Stata 16.0 software.
  8. 08HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, IDegLira required lower daily insulin doses than insulin degludec.

    In plain wordsIn adults with type 2 diabetes, IDegLira required lower daily insulin doses than insulin degludec.

    Peptide
    Liraglutide
    Outcome
    DecreaseDaily insulin dose
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Additionally, patients treated with IDegLira required significantly lower daily insulin doses.
    4 context sentences
    Summary · context
    A comprehensive search was systematically conducted across PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov from their inception until March 11, 2025.
    Summary · context
    The search focused on randomized controlled trials (RCTs) that compared IDegLira with insulin degludec in adult patients with T2D.
    Summary · context
    The primary outcomes of interest included change in glycated hemoglobin (HbA1c) and body weight.
    Summary · context
    Random-effects meta-analyses were performed using RevMan 5.4 and Stata 16.0 software.
  9. 09HumanSystematic reviewSafety outcome

    In adults with type 2 diabetes, severe or blood glucose-confirmed symptomatic hypoglycemia was comparable with IDegLira and insulin degludec.

    In plain wordsIn T2D adults, severe or glucose-confirmed symptomatic hypoglycemia was reportedly comparable for IDegLira versus insulin degludec; the significance test was unstated.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedSevere or blood glucose-confirmed symptomatic hypoglycemia
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Notably, the risk of severe or blood glucose-confirmed symptomatic hypoglycemia, adverse events, and severe adverse events was comparable between IDegLira and insulin degludec.
    4 context sentences
    Summary · context
    A comprehensive search was systematically conducted across PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov from their inception until March 11, 2025.
    Summary · context
    The search focused on randomized controlled trials (RCTs) that compared IDegLira with insulin degludec in adult patients with T2D.
    Summary · context
    The primary outcomes of interest included change in glycated hemoglobin (HbA1c) and body weight.
    Summary · context
    Random-effects meta-analyses were performed using RevMan 5.4 and Stata 16.0 software.
  10. 10HumanSystematic reviewSafety outcome

    In adults with type 2 diabetes, adverse events were comparable with IDegLira and insulin degludec.

    In plain wordsIn T2D adults, adverse events were reportedly comparable with IDegLira versus insulin degludec; the significance test was unstated.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedAdverse events
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Notably, the risk of severe or blood glucose-confirmed symptomatic hypoglycemia, adverse events, and severe adverse events was comparable between IDegLira and insulin degludec.
    4 context sentences
    Summary · context
    A comprehensive search was systematically conducted across PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov from their inception until March 11, 2025.
    Summary · context
    The search focused on randomized controlled trials (RCTs) that compared IDegLira with insulin degludec in adult patients with T2D.
    Summary · context
    The primary outcomes of interest included change in glycated hemoglobin (HbA1c) and body weight.
    Summary · context
    Random-effects meta-analyses were performed using RevMan 5.4 and Stata 16.0 software.
  11. 11HumanSystematic reviewSafety outcome

    In adults with type 2 diabetes, severe adverse events were comparable with IDegLira and insulin degludec.

    In plain wordsIn T2D adults, severe adverse events were reportedly comparable with IDegLira versus insulin degludec; the significance test was unstated.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedSevere adverse events
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Notably, the risk of severe or blood glucose-confirmed symptomatic hypoglycemia, adverse events, and severe adverse events was comparable between IDegLira and insulin degludec.
    4 context sentences
    Summary · context
    A comprehensive search was systematically conducted across PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov from their inception until March 11, 2025.
    Summary · context
    The search focused on randomized controlled trials (RCTs) that compared IDegLira with insulin degludec in adult patients with T2D.
    Summary · context
    The primary outcomes of interest included change in glycated hemoglobin (HbA1c) and body weight.
    Summary · context
    Random-effects meta-analyses were performed using RevMan 5.4 and Stata 16.0 software.
  12. 12HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, IDegLira produced a higher proportion achieving HbA1c below 7.0% without weight gain and severe or blood glucose-confirmed hypoglycemic episodes than insulin degludec.

    In plain wordsIn T2D adults, IDegLira increased HbA1c <7.0% attainment without weight gain or severe or glucose-confirmed hypoglycemia versus insulin degludec.

    Peptide
    Liraglutide
    Outcome
    IncreaseHbA1c below 7.0% without weight gain and hypoglycemia
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In comparison to insulin degludec, IDegLira demonstrated superior blood glucose control, as evidenced by a higher proportion of patients achieving HbA1c levels below 7.0% and 6.5%, as well as those achieving these targets without weight gain and severe or blood glucose-confirmed hypoglycemic episodes.
    4 context sentences
    Summary · context
    A comprehensive search was systematically conducted across PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov from their inception until March 11, 2025.
    Summary · context
    The search focused on randomized controlled trials (RCTs) that compared IDegLira with insulin degludec in adult patients with T2D.
    Summary · context
    The primary outcomes of interest included change in glycated hemoglobin (HbA1c) and body weight.
    Summary · context
    Random-effects meta-analyses were performed using RevMan 5.4 and Stata 16.0 software.
  13. 13HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, IDegLira produced a higher proportion achieving HbA1c below 6.5% without weight gain and severe or blood glucose-confirmed hypoglycemic episodes than insulin degludec.

    In plain wordsIn T2D adults, IDegLira increased HbA1c <6.5% attainment without weight gain or severe or glucose-confirmed hypoglycemia versus insulin degludec.

    Peptide
    Liraglutide
    Outcome
    IncreaseHbA1c below 6.5% without weight gain and hypoglycemia
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In comparison to insulin degludec, IDegLira demonstrated superior blood glucose control, as evidenced by a higher proportion of patients achieving HbA1c levels below 7.0% and 6.5%, as well as those achieving these targets without weight gain and severe or blood glucose-confirmed hypoglycemic episodes.
    4 context sentences
    Summary · context
    A comprehensive search was systematically conducted across PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov from their inception until March 11, 2025.
    Summary · context
    The search focused on randomized controlled trials (RCTs) that compared IDegLira with insulin degludec in adult patients with T2D.
    Summary · context
    The primary outcomes of interest included change in glycated hemoglobin (HbA1c) and body weight.
    Summary · context
    Random-effects meta-analyses were performed using RevMan 5.4 and Stata 16.0 software.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.